Compare Abeona Therapeutics Inc (ABEO) vs Nvidia Corp (NVDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nvidia Corp — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Nvidia Corp trades at $203.91 (market cap $4.77T). The key difference: Nvidia Corp is far larger — about 12777.2× Abeona Therapeutics Inc's market cap, and Nvidia Corp pays a 0.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NVDA | |
|---|---|---|
Market Cap | $373.32M | $4.77T |
Sector | Health | Technology |
52-Week High | $7.23 | $235.75 |
52-Week Low | $4.17 | $160.00 |
Enterprise Value | $228.22M | $4.70T |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NVIDIA (NVDA) trades at $204.27, up 4.46% today, with a bearish technical signal but strong fundamentals. The stock faces resistance near $207, with support at $193. Revenue surged to $130.50B in 2025, with a net income margin of 62.97%, while valuation ratios like P/E of 30.16 reflect high growth expectations. Recent news highlights AI-driven growth but also concerns over peak spending and competition.
Outlook remains positive due to AI leadership and earnings beats, but risks include market volatility and competitive pressures. Analysts project a $324.95 price target with 75% buy ratings, suggesting upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
